Regulus Therapeutics Inc [NASDAQ: RGLS] jumped around 2519991.86 points on Tuesday, while shares priced at $2520000.0 at the close of the session, up 9272704%.
Regulus Therapeutics Inc stock is now 223.81% up from its year-to-date (YTD) trading value. RGLS Stock saw the intraday high of $8.18 and lowest of $8.07 per share. The company’s 52-week high price is 8.35, which means current price is +883.01% above from all time high which was touched on 06/09/25.
Compared to the average trading volume of 2.52M shares, RGLS reached a trading volume of 9272704 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Regulus Therapeutics Inc [RGLS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RGLS shares is $8.80 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RGLS stock is a recommendation set at 2.67. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for Regulus Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on March 27, 2025. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on August 02, 2024, representing the official price target for Regulus Therapeutics Inc stock. Previously, the target price had yet another raise to $6, while Leerink Partners analysts kept a Outperform rating on RGLS stock.
The Price to Book ratio for the last quarter was 7.84, with the Price to Cash per share for the same quarter was set at 0.95.
How has RGLS stock performed recently?
Regulus Therapeutics Inc [RGLS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.73. With this latest performance, RGLS shares gained by 3.16% in over the last four-week period, additionally plugging by 440.40% over the last 6 months – not to mention a rise of 416.46% in the past year of trading.
Regulus Therapeutics Inc [RGLS]: Deeper insight into the fundamentals
Return on Equity for this stock declined to -50.30%, with Return on Assets sitting at -50.30%.
Earnings analysis for Regulus Therapeutics Inc [RGLS]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RGLS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Regulus Therapeutics Inc go to 11.89%.
Insider trade positions for Regulus Therapeutics Inc [RGLS]
There are presently around $82.87%, or 85.18% of RGLS stock, in the hands of institutional investors. The top three institutional holders of RGLS stocks are: FEDERATED HERMES, INC. with ownership of 12.85 million shares, which is approximately 19.9374%. RA CAPITAL MANAGEMENT, L.P., holding 6.25 million shares of the stock with an approximate value of $$11.16 million in RGLS stocks shares; and RA CAPITAL MANAGEMENT, L.P., currently with $$8.93 million in RGLS stock with ownership which is approximately 7.7561%.
